- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Wayne Kuznar | Authors
Articles
Newly Diagnosed Acute GVHD Shows Benefit With Itolizumab Use
February 18, 2021
A promising approach to treating newly diagnosed acute graft-versus-host disease emerges, based on data regarding the use of the humanized IgG1 monoclonal antibody itolizumab.
Radical Prostatectomy as Primary Treatment for Prostate Cancer Leads to Better Survival
June 16, 2020
Results presented at the American Urological Association 2020 Virtual Meeting demonstrated that of men who received prior RT or surgery for localized prostate cancer, those that had RT were found to have a 32% higher risk of developing castrate-resistant disease.
Ibrutinib/Rituximab Combo Induced Superior PFS in Older Patients with CLL
December 09, 2019
The combination of ibrutinib and rituximab demonstrated superior progression-free survival in older patients with previously untreated chronic lymphocytic leukemia.
Frontline Triplet Regimen Induces Undetectable MRD in the Bone Marrow of Patients with CLL
December 09, 2019
The triplet regimen consisting of acalabrutinib, venetoclax, and obinutuzumab appeared highly active as frontline therapy for patients with chronic lymphocytic leukemia.
Liso-Cel Shows Promise in Relapsed/Refractory Large B-Cell Lymphoma
December 09, 2019
Lisocabtagene maraleucel induced high response rates in patients with aggressive relapsed/refractory large B-cell lymphoma.